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We have recently demonstrated the 
ability of a prostatic acid phosphatase 
(PAP)-derived 15-mer peptide (PAP-
114) to reduce the growth of established 
TRAMP C1 tumors in a preclinical 
murine model.1 Although these results are 
encouraging and illustrate the potential of 
vaccine-based immunotherapy, they were 
obtained using relatively young animals 
(maximum 12 w of age, which equates to 
10–20 y in humans). Thus, our findings 
might not represent the responsiveness/
effectiveness of anti-cancer vaccines in old 
mice or in prostate patients, the average 
age of whom is 65 y.
Overall, both the innate and adap-
tive immune systems are attenuated dur-
ing senescence, and this is manifested, in 
part at least, by a general decline in the 
diversity of the T cell repertoire, a reduc-
tion in the number of naïve T cells and 
a proportional increase in the prevalence 
of memory T cells. Senescence is associ-
ated by a limited proliferative potential 
and a chronic low-grade systemic inflam-
mation.2 It is therefore important that the 
development of vaccines and their transla-
tion into the clinic take into consideration 
the influence of age and other factors on 
their efficacy. In this setting, the nutri-
tional, physical, and psychological status 
of patients are indeed critical for improv-
ing their “immunological fitness.”
Although preclinical models do not 
entirely reflect the clinical situation and 
have other limitations, they do have mer-
its. We propose that long peptides not only 
induce stronger, antigen-specific immune 
responses, thereby potentially limiting the 
induction of regulatory T (Treg) cells, 
but that they also are cheaper and easier 
to manufacture to a clinical grade than 
whole protein-based vaccines. The path 
towards the development of peptide-based 
vaccines involves the identification of 
relevant immunogenic regions in tumor-
associated antigens, followed by studies 
in wild-type or humanized (expressing 
human MHC molecules) mice (Fig. 1). 
The relative efficacy of different vaccine 
formulations, including purified peptides, 
peptides linked to delivery systems or pep-
tide-coding cDNA (administered with or 
without adjuvants), is also an important 
parameter to assess, as is the influence of 
the concomitant administration of immu-
nomodulatory agents on the development 
of effective anti-cancer immune responses. 
An example of the latter is a monoclonal 
antibody  against CD274 (best known 
as PD-L1), which influences the pres-
ence and immunosuppressive activity of 
Treg cells (so-called “immune checkpoint 
blockade”). The widespread adoption of 
anti-cancer vaccines into clinical practice 
requires the development of optimized for-
mulations and approaches that are capable 
of1 breaking immunological tolerance;2 
overcoming local and systemic tumor-
driven immunosuppression;3 operate in 
spite of age-related immune dysfunctions; 
and4 targeting metastatic disease. These 
issues can be investigated (and potentially 
addressed) using induced, engineered and 
spontaneous heterotopic and orthotopic 
mouse tumor models (Fig. 1).
Although orthotopic models might 
be considered less relevant than geneti-
cally modified models, they do allow for 
the assessment of vaccine efficacy and the 
influence of age-related immune dysfunc-
tion in old mice. Recently, Bouchlaka 
et al., found that macrophages from old 
mice and elderly people produce higher 
levels of tumor necrosis factor α (TNFα) 
and interleukin (IL)-6 than macrophages 
derived from young mice and humans.3 
Age therefore dictates the ability of 
some cells to produce pro-inflammatory 
cytokines, a phenomenon that has been 
referred to as “inflammaging”4. It has also 
been demonstrated that the attenuated 
response to vaccines in old mice/patients 
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vaccine-based immunotherapy can increase the overall survival of patients with advanced prostate cancer. however, 
the efficacy of vaccine-elicited anticancer immune responses is heavily influenced by the physical, nutritional, and psy-
chological status of the patient. Given their importance, these parameters should be carefully considered for the design 
of future clinical trials testing this immunotherapeutic paradigm in prostate cancer patients.
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Figure 1. Important steps to be taken from the formulation of an anticancer vaccine to the implementation of clinical trials. The development of a pros-
tate acid phosphatase (PaP)-targeting vaccine for the treatment of prostate carcinoma patients is employed as an example. CTL, cytotoxic T lymphocyte.
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can be partially restored by the inclu-
sion of additional co-stimulatory signals. 
Thus, it is essential to demonstrate the 
efficacy of vaccines destined to old can-
cer patients in preclinical models that are 
based on appropriately aged animals.
An essential and substantive propor-
tion of immune responses is generated at 
the mucosae of the gastrointestinal sys-
tem, and this is driven (or at least mod-
ulated) by gut microflora.5 The gut 
microflora can indeed influence vari-
ous immunological functions, including 
the establishment of anti-inflammatory 
responses.6 Although people over 60 typi-
cally exhibit a marked reduction in the 
intestinal bacteria that are known to for-
tify gastrointestinal health, this defect can 
be resolved, at least partially, using pro-
biotics that are specifically fermented by 
the beneficial microbiota in the gut (e.g., 
galactooligosaccharides). The importance 
of the gut microflora for the development 
of anti-cancer immunity has recently been 
illustrated by reports that the temporary 
disappearance of the microbiota upon 
antibiotic treatment reduces the anti-neo-
plastic efficacy of chemotherapy alone or 
chemotherapy combined with immuno-
therapy.7 An inappropriate diet, the lack 
of specific digestive enzymes and other 
factors including the general physical and 
psychological health also influence immu-
nological functions in humans.
The ability of stress to accelerate the 
effects of aging on immunity8 and influ-
ence the efficacy of vaccination should 
also be considered in the design, trans-
lation, and clinical implementation of 
therapeutic vaccines.9 Each patient is 
unique with respect to their neoplasm, 
gut microbiota, and general immunologi-
cal status. Moreover, the mental attitude 
of individual patients toward their disease 
and their experience of living with cancer 
vary to a significant degree, and recent 
research has demonstrated that psycho-
logical and/or behavioral factors can 
influence tumor incidence and/or pro-
gression.10 Similarly, an increasing number 
of studies has highlighted the health ben-
efits that are associated with positive emo-
tions. However, to date, no clinical trial 
has attempted to restore/improve the 
patient’s intestinal microbiota while pro-
viding psychological interventions that are 
aimed at minimizing patient-to-patient 
differences and maximizing the efficacy 
of vaccination prior to, or throughout 
immunotherapy.
In summary, immunity is influenced 
by dietary factors which influence the gut 
flora, the general state of health, and the 
psychological capacity of an individual to 
cope with stress. Although not all of these 
parameters can be studied and manipu-
lated in a clinical trial, the restoration/
improvement of the gut microbiome and 
the improvement of the psychological sta-
tus of the patient would be relatively easy 
and cost-effective to evaluate.
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